What evidence do we need to support the use of extended pelvic lymph node dissection in prostate cancer?

Eur Urol. 2015 Apr;67(4):597-8. doi: 10.1016/j.eururo.2014.09.025. Epub 2014 Oct 1.

Authors

Alberto Briganti¹, Gianluca Giannarini², R Jeffrey Karnes³, Giorgio Gandaglia⁴, Vincenzo Ficarra², Francesco Montorsi⁴

Affiliations

¹ Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: briganti.alberto@hsr.it.
² Department of Experimental and Clinical Medical Sciences, Urology Unit, University of Udine, Udine, Italy.
³ Department of Urology, Mayo Clinic, Rochester, MN, USA.
⁴ Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

PMID: 25281390
DOI: 10.1016/j.eururo.2014.09.025

No abstract available

MeSH terms

Aged
Aged, 80 and over
Humans
Laparoscopy
Lymph Node Excision / methods*
Lymph Nodes / pathology*
Lymph Nodes / surgery
Lymphatic Metastasis / diagnosis*
Male
Middle Aged
Neoplasm Staging / methods*
Pelvis / pathology*
Prostatectomy
Prostatic Neoplasms / pathology*
Prostatic Neoplasms / surgery
Risk Factors
Treatment Outcome